Sugi Predict

Sugi Predict / Compounds / SCHEMBL326799

SCHEMBL326799

SCHEMBL326799

O=C(O)C1CCN(c2ccc(F)cn2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.55
▸ HTT P42858 1/20 0.55
▸ HRH3 Q9Y5N1 2/20 0.54
▸ NOTUM Q6P988 2/20 0.54
▸ CHRM4 P08173 1/20 0.53
▸ KDM4E B2RXH2 4/20 0.52
▸ ABL1 P00519 1/20 0.52
▸ DGAT1 O75907 1/20 0.52
▸ ADORA2A P29274 1/20 0.52
▸ KCNH2 Q12809 1/20 0.52
▸ GPR119 Q8TDV5 1/20 0.51
▸ ALDH1A1 P00352 2/20 0.50
▸ MAPT P10636 2/20 0.50
▸ NPY2R P49146 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ SCN9A Q15858 1/20 0.47
▸ SLC6A9 P48067 1/20 0.47
▸ SERPINE1 P05121 1/20 0.47
▸ PDE4A P27815 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18101815 0.91 NOTUM (0.62) LMNAHRH3NOTUMCHRM4KDM4E
SCHEMBL16769733 0.87 HRH3 (0.55) LMNAHRH3CHRM4KDM4EABL1
SCHEMBL1977631 0.83 LMNA (0.56) LMNAHTTNOTUMKDM4EABL1
SCHEMBL20729339 0.83 CHRM4 (0.54) LMNAHRH3CHRM4KDM4EABL1
SCHEMBL18248410 0.83 KDM4E (0.60) LMNAHRH3CHRM4KDM4EABL1
SCHEMBL15205885 0.82 LMNA (0.55) LMNAHTTNOTUMKDM4EABL1
SCHEMBL14605216 0.82 LMNA (0.55) LMNAHTTHRH3KDM4EABL1
SCHEMBL31381164 0.82 LMNA (0.62) LMNAHTTNOTUMKDM4EABL1
SCHEMBL31381165 0.82 LMNA (0.62) LMNAHTTNOTUMKDM4EABL1
SCHEMBL239335 0.82 LMNA (0.55) LMNAHTTHRH3NOTUMKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230120185-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-04-20 — — US disclosed
US-11485710-B2 Heterocyclic amides as kinase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2022-11-01 — — US disclosed
US-11485710-B2 Heterocyclic amides as kinase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2022-11-01 — — US disclosed
US-20210253532-A1 Heterocyclic Amides as Kinase Inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-08-19 — — US disclosed
US-20210253532-A1 Heterocyclic Amides as Kinase Inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-08-19 — — US disclosed
CN-112370452-A Heterocyclic amides as kinase inhibitors 葛兰素史密斯克莱知识产权发展有限公司 2021-02-19 — — CN disclosed
US-10899716-B2 Heterocyclic amides as kinase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-01-26 — — US disclosed
EP-3298002-B1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2020-12-16 — — EP disclosed
EP-3298002-B1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2020-12-16 — — EP disclosed
CN-107624111-B Heterocyclic amides as kinase inhibitors 葛兰素史密斯克莱知识产权发展有限公司 2020-11-03 — — CN disclosed
US-20120178761-A1 PYRROLIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2012-07-12 — — US disclosed
WO-2012004207-A1 (3 -METHYLPYRROLIDIN- 3 - YL) METHYL PYRIDINYL ETHER DERIVATIVES AND THEIR USE AS NK-3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2012-01-12 — — WO disclosed
US-20120010212-A1 METHYL-PYRROLIDINE ETHER DERIVATIVES HOFFMANN-LA ROCHE INC. 2012-01-12 — — US disclosed
WO-2011085886-A1 PYRROLIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-07-21 — — WO disclosed
WO-2011085886-A1 PYRROLIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-07-21 — — WO disclosed
US-20110152233-A1 PYRROLIDINE COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2011-06-23 — — US disclosed
WO-2011073160-A1 PYRROLIDINE DERIVATIVES AS NK - 3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2011-06-23 — — WO disclosed
US-20110144081-A1 PYRROLIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-06-16 — — US disclosed
US-20110144081-A1 PYRROLIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-06-16 — — US disclosed
US-20110144081-A1 PYRROLIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-06-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144081-A1 PYRROLIDINE DERIVATIVES TACR1, OPRL1, SLC6A3 LMNA 4722/4885HTT 590/4885HRH3 201/4885
US-20210253532-A1 Heterocyclic Amides as Kinase Inhibitors MAP3K19, MAP3K20, MAP3K1 LMNA 4043/4885HTT 4415/4885HRH3 649/4885
US-20110152233-A1 PYRROLIDINE COMPOUNDS SLC6A3, OPRL1, OPRK1 LMNA 4701/4885HTT 420/4885HRH3 235/4885
US-20230120185-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS MAP3K19, MAP3K20, MAP3K1 LMNA 4043/4885HTT 4415/4885HRH3 649/4885
US-20120010212-A1 METHYL-PYRROLIDINE ETHER DERIVATIVES OPRM1, OPRK1, OPRD1 LMNA 4706/4885HTT 1541/4885HRH3 1070/4885
US-11485710-B2 Heterocyclic amides as kinase inhibitors MAP3K19, MAP3K20, MAP3K1 LMNA 4043/4885HTT 4415/4885HRH3 649/4885
US-10899716-B2 Heterocyclic amides as kinase inhibitors MAP3K19, MAP3K20, MAP3K1 LMNA 4043/4885HTT 4415/4885HRH3 649/4885
US-20120178761-A1 PYRROLIDINE DERIVATIVES SLC6A3, NPSR1, TACR1 LMNA 4753/4885HTT 573/4885HRH3 145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.